So Called 'Next Big Thing' Now Available to Cosmetics Marketers, Manufacturers



    Botaneco Unveils Hydresia(TM) Base Emulsion System During Chemist Show

    CALGARY, Oct. 3 /CNW/ - Consumers may never look at their cosmetics,
sunscreen, body lotion or moisturizer the same way again, as the way in which
many personal care items are developed is about to change. With the official
release of the first branded line of oilbody based ingredients from Botaneco,
the newly unveiled Hydresia(TM) represents not only a technological and
performance breakthrough, it has also been closely scrutinized under the
microscope of brand executives to gauge consumer potential.
    Both have proven to be a resounding success.
    The performance of Hydresia(TM) was equal to or better than current
cosmetic industry mainstays such as petroleum, animal byproducts or chemically
derived products in terms of superior hydration and skin barrier protection
The product also boasts a number of naturally occurring benefits not provided
by traditional methods, including an all natural base that acts as an
emulsifier, emollient and moisturizer all in one. It has natural antioxidant
properties, and uses less energy in the creation of finished goods because of
its cold process formulation. The complete Hydresia(TM) spec sheet is
available at www.hydresia.com.
    Botaneco managing director, Nancy Markley, Ph.D., is actively working
with potential marketing partners to encourage the use of Hydresia(TM) as a
base emulsion, similar to such well known cobranded "ingredients inside" as
Splenda(R) and Intel(R). Botaneco has conducted an extensive branding process
to objectively test the new product, its benefits and even its name and logo.
Working with marketing and brand experts Eisen Management Group and AcuPOLL
Research, the product was market tested for interest among consumers and
positive impact to a finished good. The complete results of this study are
available at www.hydresia.com.
    "The Hydresia(TM) brand performed beautifully in early market tests. Not
only is Hydresia(TM) a better mouse trap, we know that consumers want it,"
Markley continued. "The product qualities and benefits received the highest
possible rating among consumers in terms of general interest in trying a
product that contains Hydresia(TM) because of its superior hydration and
moisturization qualities, and because its provides a high performance yet all
natural choice. So, if a cosmetics or personal care marketer or manufacturer
is looking for a product extension, entry into the rapidly growing naturals
segments or in just improving the performance of their current products
Hydresia(TM) is a very smart choice."
    Botaneco continues to work with its marketing partners to build awareness
and generate trial among consumers regarding the naturally occurring benefits
and performance qualities of Hydresia(TM) as part of their "Intelligent
Beauty" educational campaign. The new branded line was introduced last evening
during a special VIP reception during the Society of Cosmetic Chemists trade
show in Los Angeles, and officially launches today at the trade show.

    About Botaneco

    From development through delivery, Botaneco is a performance based,
technologically advanced botanical science organization that manufactures and
markets a branded line of products that harness the naturally occurring
benefits of protein protected seed oils. Botaneco provides performance,
innovation and choice in creating natural, renewable and versatile delivery
systems and ingredients used in the development of cosmetics, personal care
and prescription topical/dermatology products beneficial to humans and the
environment. Botaneco is a business unit of Calgary-based biotechnology
company SemBioSys. More information can be accessed at www.botaneco.ca.

    About SemBioSys (TSX:SBS)

    With headquarters in Calgary, Alberta, SemBioSys Genetics Inc. is a
biotechnology company developing protein-based pharmaceuticals for metabolic
and cardiovascular diseases. The Company's lead pharmaceutical candidates are
recombinant human insulin to serve the rapidly expanding global diabetes
market and Apo AI, a next generation cardiovascular drug. In addition to its
pharmaceutical products, SemBioSys is developing a series of
non-pharmaceutical products addressing animal and aquaculture health,
nutritional oils and human topical markets. More information is available and
can be accessed at www.sembiosys.com.

    This press release contains certain forward-looking statements,
including, without limitation, statements containing the words "believe",
"may", "plan", "will", "estimate", "continue", "anticipate", "intend",
"expect" and other similar expressions which constitute "forward-looking
information" within the meaning of applicable Canadian securities laws.
Forward-looking statements reflect the Company's current expectation and
assumptions, and are subject to a number of risks and uncertainties that could
cause actual results to differ materially from those anticipated. These
forward-looking statements involve risks and uncertainties including, but not
limited to, changing market conditions, the successful and timely completion
of clinical studies, the establishment of corporate alliances, the impact of
competitive products and pricing, new product development, uncertainties
related to the regulatory approval process and other risks detailed from
time-to-time in the Company's ongoing filings with the Canadian securities
regulatory authorities which filings can be found at www.sedar.com. Given
these risks and uncertainties, readers are cautioned not to place undue
reliance on such forward-looking statements. The Company undertakes no
obligation to publicly update or revise any forward-looking statements either
as a result of new information, future events or otherwise, except as required
by applicable Canadian securities laws.

    %SEDAR: 00020947E




For further information:

For further information: Media Contact: Rodger Roeser, APR, Eisen
Management Group, (859) 586-4302, rroeser@eisenmanagementgroup.com; Botaneco,
Nancy Markley, Ph.D., Managing Director, Ph: (403) 717-8774, Fax: (403)
250-3886, Email: markleyn@sembiosys.com, Internet: www.botaneco.ca

Organization Profile

SemBioSys Genetics Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890